Cell therapy technologies market seen reaching $11.35 billion by 2030

The cell therapy technologies market is projected to grow from $5.67 billion in 2025 to $11.35 billion by 2030, according to The Business Research Company. The report points to rising cancer rates, more regenerative medicine research, and automation in manufacturing as the main growth drivers.

Why it matters: - The cell therapy technologies market is moving toward faster adoption in cancer care, regenerative medicine and advanced manufacturing. - The market’s projected growth signals expanding demand for tools that help develop, process and commercialize living-cell therapies. - Faster scaling could affect drugmakers, research labs and hospitals as cell-based treatments move closer to routine use.

What happened: - The Business Research Company released its Cell Therapy Technologies Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the market will rise from $5.67 billion in 2025 to $6.52 billion in 2026. - The report forecasts the market will reach $11.35 billion by 2030, implying a 14.8% compound annual growth rate. - The release says North America held the largest market share in 2025. - The release says Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - Cell therapy uses living cells to treat medical conditions by modifying cells outside the body and then reintroducing them into patients. - The historical growth drivers cited in the report include more clinical research on cell-based therapies, wider adoption of stem cell treatments, growth in research cell banks, access to advanced bioprocessing equipment, and progress in translational medicine programs. - The forecast period growth is linked to more commercialization of cell therapies, higher investment in regenerative medicine, expansion of point-of-care cell therapy platforms, rising demand for automated manufacturing workflows, and tighter regulatory focus on process consistency. - The report highlights broader use of closed-system cell processing platforms, automated cell culture systems, scalable manufacturing solutions, improved process monitoring and quality control tools, and standardized cell handling procedures. - Cancer prevalence is another growth driver. - The American Cancer Society reported 2,001,140 cancer cases in the US in January 2024, up from 1,958,310 the year before, a 2.19% increase. - The regional review covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The company offers a free sample of the report and a full market report.

Between the lines: - The growth outlook reflects both scientific progress and industrialization of cell therapy production. - Automation and closed systems point to a market shifting from niche lab workflows toward more standardized, scalable manufacturing. - The cancer link matters because a larger patient pool can translate into more demand for cell-based treatment platforms and supporting technologies.

What's next: - The market’s next phase will likely center on manufacturing scale, workflow automation and quality control. - Regional momentum will be important, with Asia-Pacific positioned to outpace other markets in growth. - More commercialization of cell therapies should keep pressure on suppliers of processing systems, monitoring tools and production infrastructure.

The bottom line: - Cell therapy technologies are evolving from a research-heavy category into a fast-growing commercial market, with automation and cancer treatment demand shaping the outlook.